Filing Flows

Filing Flows › Companies › vTv Therapeutics › Cash flow

vTv Therapeutics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$10.2M in Q3 2026 · −$21.7M over twelve months

Operating cash flow−$10.2M
Free cash flow−$10.2M

Analysis

In Q3 2026, vTv Therapeutics generated −$10.2M of operating cash flow. That is $5.0M less than in Q3 2025 (−$5.2M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$21.7M; the largest uses were operating cash flow ($21.7M), net borrowing (+) / repaid (−) ($328K); besides operations, cash came from other financing ($392K), shares issued ($324K); the cash balance fell by $21.3M.

Operating cash flow was −$10.2M against net income of −$11.6M. The largest differences: stock-based pay +$2.0M, prepaid and other assets −$806K, payables +$32K.

Free cash flow

vTv Therapeutics: free cash flow by quartervTv Therapeutics: free cash flow by quarter−$4.8MQ4 2024−$5.7MQ1 2025−$5.1MQ2 2025−$5.2MQ3 2025−$9.3MQ4 2025$9.2MQ1 2026−$11.4MQ2 2026−$10.2MQ3 2026
Operating cash flow less capital spending.
vTv Therapeutics: operating cash flow against capital spendingvTv Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$4.8M$0Q4 2024−$5.7M$0Q1 2025−$5.1M$0Q2 2025−$5.2M$0Q3 2025−$9.3M$0Q4 2025$9.2M$0Q1 2026−$11.4M$0Q2 2026−$10.2M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$10.2M, Capital spending $0.

Capital allocation, year by year

vTv Therapeutics: where the cash came from (up) and went (down), by fiscal yearvTv Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$19.3MFY2021: Net borrowing $172KFY2021: Shares issued $26.8M$27.0MFY2021FY2022: Operating cash flow −$16.0MFY2022: Net borrowing −$32KFY2022: Capital spending −$21KFY2022FY2023: Operating cash flow −$19.1MFY2023: Net borrowing −$33KFY2023FY2024: Operating cash flow −$25.3MFY2024: Net borrowing −$191KFY2024: Shares issued $2.5M$2.5MFY2024FY2025: Operating cash flow −$25.3MFY2025: Shares issued $16K$16KFY2025
Over these 5 years operating cash flow totalled −$105M; the largest uses were operating cash flow ($105M) and net borrowing ($256K). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$77.2M
Debtnone
Net cash$77.2M
Cash runway3.6 years

vTv Therapeutics is burning cash: its operations consume cash, a free cash flow of −$21.7M a year at the current rate against $77.2M of cash and investments: a runway of about 3.6 years before any new financing.

Where the cash came from and went

vTv Therapeutics: sources (+) and uses (−) of cash, Q3 2026vTv Therapeutics: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$10.2MCash drawn (+) / kept (−)$9.5MOther financing$392KShares issued$317K
vTv Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026vTv Therapeutics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$21.7MCash drawn (+) / kept (−)$21.3MOther financing$392KNet borrowing (+) / repaid (−)−$328KShares issued$324K

From profit to cash

vTv Therapeutics: net income to operating cash flow, Q3 2026vTv Therapeutics: net income to operating cash flow, Q3 2026Net income−$11.6MDepreciation & amortization$1KStock-based pay$2.0MPayables$32KPrepaid and other assets−$806KOperating cash flow−$10.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$10.2M—$317K$9.5M−$10.2M
Q2 2026−$11.4M——$11.4M−$11.4M
Q1 2026$9.2M——−$9.2M$9.2M
Q4 2025−$9.3M−$328K$7K$9.6M−$9.3M
Q3 2025−$5.2M−$64K—−$72.6M−$5.2M
Q2 2025−$5.1M——$5.1M−$5.1M
Q1 2025−$5.7M——$5.7M−$5.7M
Q4 2024−$4.8M——$4.8M−$4.8M

vTv Therapeutics: income statement and cash flow

vTv Therapeutics, Q1 2026: revenue $36.8M, operating margin 63.1%. The chart follows the revenue to costs, profit and cash.

vTv Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.